市场调查报告书
商品编码
1245183
全球在线药房市场 - 按产品(OTC 产品、处方药)、地区、增长潜力、竞争市场份额、全球预测,2023-2032 年E-pharmacy Market - By Product (OTC Products, Prescription Medicine), By Region, Growth Potential, Competitive Market Share & Global Forecast, 2023 - 2032 |
到 2032 年,全球在线药店市场预计将呈现积极迹象,因为处方药可以通过在线渠道以折扣价购买。
医生处方药的合法化也将对收入产生积极影响。 此外,越来越多的初创企业正在加剧市场领导者之间的竞争。
最重要的是,电子药店使购买药品变得更加容易,特别是对于远离传统药店的人、残疾人、老年人和工作强度大的人来说。 航运也比旅行更实惠,省钱。 在线药店提供的另一个好处是节省时间。 在线药店配送以及客户隐私和机密性可以进一步加速市场动态。 根据一项调查,96% 的美国成年人表示科技让他们更容易开处方和管理药物。
市场领先的供应商正在通过併购、合作伙伴关係、研发投资和新产品发布等战略努力来提高他们在行业中的竞争力。 例如,印度电子商务巨头 Flipkart 正在洽谈收购总部位于班加罗尔的在线药店初创公司 Pharmallama。 此次收购将使 Flipkart 能够在印度推出 Flipkart Health+。
总体而言,在线药店行业在产品和区域方面存在细分。
按产品划分,伦理药品领域预计在预计期间将显着增长。 产品可用性是促进该细分市场增长的主要因素。 此外,促进处方药销售的政策改进将在未来加速分部收益。
例如,在 2023 年,亚马逊将推出一项新的处方药计划,以固定费用为订阅者提供所需的药物。 最新举措是该集团试图将科技公司推向医疗保健领域,以吸引顾客远离药店零售商。
按地区划分,2022 年亚太在线药店行业的价值将超过 190 亿美元。 初创企业的增加和主要参与者之间的新兴竞争将推动市场渗透到印度、中国和日本等新兴经济体。 毋庸置疑,折扣和奖励等产品优势将在预计期间推动市场扩张。 此外,每个国家增加对医疗基础设施发展的投资将对该地区的增长产生积极影响。
E-pharmacy Market is anticipated to showcase a positive trajectory through 2032, owing to the increasing availability of prescription drugs on online channels at discounted prices. In addition, the legalization of physician-prescribed drugs will also positively influence revenue generation. Additionally, the rising number of startups has resulted in intense competition among market leaders.
Besides, e-pharmacies have made buying drugs easy, especially for people who live far from a traditional pharmacy, disabled people, the elderly, and those who work very intensively. The shipping cost is also more affordable than traveling, saving money. Another advantage offered by e-pharmacy is timesaving. Delivery through e-pharmacies and customer privacy and confidentiality can further accelerate the market dynamics. As per a study, 96% of American adults claimed that technology has made filling prescriptions and managing medications easier for them.
Key providers in the market are engaging in strategic initiatives such as mergers and acquisitions, partnerships, R&D investments, and new product launches to gain a competitive edge in the industry. For instance, Flipkart, one of the leading Indian e-commerce giants, is in advanced talks to acquire Pharmallama, a Bengaluru-based online pharmacy startup. The acquisition has enabled Flipkart to expand its e-pharmacy offering, Flipkart Health+, across the Indian subcontinent.
Overall, the e-pharmacy industry is segmented in terms of product and region.
Based on the product, the prescription medicine segment is slated to grow considerably during the estimated timeframe. Wide and easy product availability will be a major factor contributing to segment growth. Besides, improving policies to enable the sale of prescription drugs will accelerate the segment revenue in the future.
For instance, Amazon in 2023, launched a new prescription drug program offering its subscribers with medications as per their requirement for a flat fee. The latest move is the conglomerate's bid to attract customers away from retail drug stores as tech players enter the healthcare sector.
Regionally, the Asia Pacific e-pharmacy industry was valued at over USD 19 billion in 2022. An increasing number of startups coupled with budding competition among the key players in the region would prompt market penetration across developing economies including India, China, Japan, and others. Not to mention, product benefits such as discounts and offers will boost expansion during the estimated timeframe. Furthermore, the increasing investment in developing healthcare infrastructure in various countries will positively influence regional growth.